Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 10/20 | 0.41 |
| ▸ | DRD2 | P14416 | 7/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252168 | 1.00 | CCR8 (0.46) | CCR8MTNR1BMTNR1ASMN1; SMN2HTR2B | |
| SCHEMBL3239661 | 0.94 | CCR8 (0.46) | CCR8MTNR1BMTNR1ASMN1; SMN2HTR2B | |
| SCHEMBL3239669 | 0.94 | CCR8 (0.46) | CCR8MTNR1BMTNR1ASMN1; SMN2HTR2B | |
| SCHEMBL3246012 | 0.88 | CCR8 (0.44) | CCR8MTNR1BMTNR1ASMN1; SMN2HTR2B | |
| SCHEMBL5330379 | 0.87 | KCNH2 (0.45) | CCR8SMN1; SMN2 | |
| SCHEMBL5330381 | 0.87 | KCNH2 (0.45) | CCR8SMN1; SMN2 | |
| SCHEMBL5443493 | 0.87 | KCNH2 (0.45) | CCR8SMN1; SMN2 | |
| SCHEMBL3246398 | 0.80 | KCNH2 (0.52) | — | |
| SCHEMBL3246402 | 0.80 | KCNH2 (0.52) | — | |
| SCHEMBL5246744 | 0.79 | MTNR1B (0.45) | CCR8MTNR1BMTNR1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799674-B1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | CCR8 829/4885MTNR1B 2247/4885MTNR1A 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.